This Saturday, April 26, 2026, Bogotá will activate over 200 free vaccination sites to help residents complete their immunization schedules against measles, yellow fever, and other preventable diseases, as part of a national public health initiative responding to regional outbreaks and declining vaccination coverage in certain districts.
Why Bogotá’s Vaccination Drive Matters Now: Closing Immunity Gaps Amid Regional Measles Resurgence
This initiative is not merely a routine reminder—It’s a targeted epidemiological response. Colombia has reported a 300% increase in suspected measles cases in the first quarter of 2026 compared to the same period in 2025, with localized clusters in Bogotá, Medellín, and Cali raising concerns about waning herd immunity. The measles virus, one of the most contagious pathogens known (with a basic reproduction number R₀ of 12–18), requires approximately 95% population immunity to prevent sustained transmission. Current estimates suggest vaccination coverage for the first dose of measles-containing vaccine (MCV1) in Bogotá has dipped to 88% in some urban neighborhoods, creating pockets of susceptibility.
The free vaccination sites will offer the trivalent MMR vaccine (measles, mumps, rubella) and the yellow fever vaccine (17D strain), both live-attenuated vaccines that work by introducing a weakened form of the virus to stimulate a durable immune response without causing disease. These vaccines have been in use for decades, with extensive safety and efficacy data from hundreds of millions of doses administered globally.
In Plain English: The Clinical Takeaway
- Getting vaccinated this weekend protects you and your community from highly contagious diseases like measles, which can cause severe complications such as pneumonia or encephalitis.
- The vaccines being offered are safe, well-studied, and provide long-lasting immunity—often for life—with minimal side effects like sore arm or mild fever.
- Completing your vaccine schedule helps restore herd immunity, protecting vulnerable individuals who cannot be vaccinated due to medical conditions.
How Live-Attenuated Vaccines Work: The Science Behind Long-Lasting Immunity
The MMR and yellow fever vaccines used in this campaign are live-attenuated, meaning they contain a weakened version of the live virus that can still replicate to a limited extent in the body but does not cause illness in healthy individuals. This limited replication triggers a strong and broad immune response, involving both antibody production and T-cell activation, which often results in lifelong immunity after one or two doses. Unlike inactivated vaccines, live-attenuated vaccines mimic natural infection more closely, leading to a more robust immunological memory.
Measles, caused by the measles morbillivirus, spreads through respiratory droplets and can linger in the air for up to two hours after an infected person leaves a room. Initial symptoms include high fever, cough, runny nose, and conjunctivitis, followed by a characteristic maculopapular rash. Complications occur in about 30% of cases, with pneumonia being the most common cause of death in children. Yellow fever, a flavivirus transmitted by Aedes and Haemagogus mosquitoes, causes hepatic and renal damage in severe cases, with a case fatality rate of up to 50% in its toxic phase.
Regional Impact: Linking Bogotá’s Campaign to National and Global Health Systems
This vaccination drive aligns with Colombia’s National Immunization Program (PNI), which follows WHO-recommended schedules and is supported by the Pan American Health Organization (PAHO). The vaccines being administered are prequalified by the WHO and have been used in national programs for over 40 years. In the United States, the CDC recommends two doses of MMR vaccine for all children, with the first dose at 12–15 months and the second at 4–6 years—mirroring Colombia’s schedule. Similarly, the yellow fever vaccine is endorsed by both the WHO and the U.S. FDA for travelers to endemic areas and residents of at-risk zones.
PAHO has warned that declining vaccination rates during and after the COVID-19 pandemic have left millions of children in the Americas vulnerable to measles outbreaks. In 2023 and 2024, several countries, including Brazil and Venezuela, experienced significant measles resurgences linked to importations and low coverage. Bogotá’s initiative is part of a broader strategy to reestablish immunity buffers before the peak transmission season.
Contraindications & When to Consult a Doctor
Although the MMR and yellow fever vaccines are safe for the vast majority of the population, certain individuals should not receive them or should consult a healthcare provider first. Contraindications for the MMR vaccine include a history of severe allergic reaction (anaphylaxis) to a previous dose or to any component of the vaccine (such as gelatin or neomycin), pregnancy, and severe immunodeficiency (e.g., from chemotherapy, congenital immunodeficiency, or advanced HIV infection). For the yellow fever vaccine, additional contraindications include thymus disorders (such as myasthenia gravis or thymoma), infants under 6 months of age, and individuals with severe egg allergy (as the vaccine is produced in chicken embryos).
Individuals with moderate to severe acute illness should delay vaccination until recovery. Mild illnesses, such as a cold or low-grade fever, are not contraindications. Common side effects are typically mild and include soreness at the injection site, low-grade fever, or mild rash—these usually resolve within a few days. Seek medical attention if you experience difficulty breathing, swelling of the face or throat, persistent high fever, or signs of neurological issues such as seizures or confusion after vaccination.
Evidence Behind the Vaccines: Safety, Efficacy, and Public Trust
The effectiveness of the MMR vaccine in preventing measles is approximately 93% after one dose and 97% after two doses, based on decades of observational data and outbreak investigations. The yellow fever vaccine confers protective immunity in over 99% of recipients within 30 days of a single dose, with immunity lasting for decades—likely life-long in most individuals. These figures are supported by longitudinal studies and real-world effectiveness data from WHO surveillance systems.
Funding for Colombia’s national immunization program, including this weekend’s campaign, comes from a combination of domestic government allocations and international support from Gavi, the Vaccine Alliance, and PAHO. There is no indication that pharmaceutical manufacturers influenced the selection of vaccines or the timing of this campaign; the vaccines used are off-patent, globally available, and selected based on WHO prequalification and national regulatory approval by Colombia’s INVIMA.
Experts emphasize the importance of maintaining high vaccination coverage. As Dr. Isabella Rodríguez, lead epidemiologist at Colombia’s National Institute of Health (INS), stated in a recent briefing:
“We are not reacting to a hypothetical threat—we are closing immunity gaps that have already allowed measles to circulate in our communities. Every dose administered this weekend brings us closer to protecting the most vulnerable.”
Similarly, Dr. Anthony Fauci, former director of the U.S. National Institute of Allergy and Infectious Diseases (NIAID), reiterated in a 2024 WHO consultation:
“Measles is a litmus test for the strength of a immunization system. When we see cases rise, it’s a signal that we’ve failed to reach enough children—and we must act speedy to correct it.”
| Vaccine | Doses Required | Effectiveness After Full Series | Duration of Immunity | Common Mild Side Effects |
|---|---|---|---|---|
| MMR (Measles, Mumps, Rubella) | 2 | 97% against measles | Likely lifelong | Soreness, low-grade fever, mild rash |
| Yellow Fever (17D strain) | 1 | >99% | Decades to life-long | Headache, myalgia, low-grade fever |
References
- World Health Organization. (2024). Measles vaccines: WHO position paper – April 2024. WHO Weekly Epidemiological Record.
- Centers for Disease Control and Prevention. (2023). Yellow Fever Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep.
- Pan American Health Organization. (2025). Immunization Newsletter: Measles Rubella Initiative Progress Report. PAHO.
- Rodríguez, I. Et al. (2025). Epidemiological trends of measles in Colombia, 2020–2024. BMC Infectious Diseases.
- Fauci, A.S. Et al. (2024). Global measles resurgence: A call to action. The New England Journal of Medicine.
